MedTrace Logo

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

NCT00698230 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2018-02-14

No results posted yet for this study

Summary

Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.

Conditions

Interventions

DRUG

INCB013739

INCB013739 5 mg QD tablet

DRUG

INCB013739

INCB013739 15 mg QD tablet

DRUG

INCB013739

INCB013739 50 mg QD tablet

DRUG

INCB013739

INCB013739 100 mg QD tablet

DRUG

INCB013739

INCB013739 200 mg QD

DRUG

Placebo comparator matching INCB013739

Orally once daily tablet

DRUG

Metformin

Sponsors & Collaborators

Principal Investigators

  • Bill Williams, MD · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-04-30
Completion
2009-05-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00698230 on ClinicalTrials.gov